Gilead Sciences (GILD) Land & Improvements (2010 - 2011)
Gilead Sciences (GILD) reported Land & Improvements of $149.4 million for Q4 2011, up 8.39% on a YoY basis from $137.8 million in Q4 2010, and up 8.39% quarter-over-quarter from $137.8 million in Q4 2010.
Gilead Sciences (GILD) Land & Improvements (2010 - 2011) Analysis & Trends
Gilead Sciences has reported Land & Improvements for 2 years, with the latest figure at $149.4 million in Q4 2011.
- For the quarter ending Q4 2011, Land & Improvements rose 8.39% year-over-year to $149.4 million; the trailing twelve-month figure through Dec 2011 stood at $149.4 million (up 8.39% YoY), and the FY2011 full-year result was $149.4 million, up 8.39% from the prior year.
- Land & Improvements for Q4 2011 stood at $149.4 million, up from $137.8 million in the prior quarter.
- The five-year high for Land & Improvements was $149.4 million in Q4 2011, with the low at $137.8 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 157.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 149.38 Mn |
| Dec 31, 2010 | 137.81 Mn |